Should the sympathetic nervous system be a target to improve cardiometabolic risk in obesity?

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 309, Issue 2, 2015, Pages H244-H258

  Lambert, Elisabeth A ^a,b   Straznicky, Nora E ^a   Dixon, John B ^a   Lambert, Gavin W ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Obesity; Sympathetic nervous system

Indexed keywords

ADIPOSE TISSUE; ADRENERGIC SYSTEM; CARDIOMETABOLIC RISK; FOOD INTAKE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; KIDNEY DENERVATION; OBESITY; PRIORITY JOURNAL; REVIEW; SYMPATHETIC TONE; ANIMAL; CARDIOVASCULAR DISEASES; COMPLICATION; METABOLISM; NERVE CELL INHIBITION; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR; SIGNAL TRANSDUCTION;

ADIPOCYTOKINE; AUTACOID;

ADIPOKINES; ADIPOSITY; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION MEDIATORS; INTRA-ABDOMINAL FAT; NEURAL INHIBITION; OBESITY; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION; SYMPATHETIC NERVOUS SYSTEM;

EID: 84937395446     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00096.2015     Document Type: Review

References (182)

1. Agapitov AV, Correia ML, Sinkey CA, Haynes WG. Dissociation between sympathetic nerve traffic and sympathetically mediated vascular tone in normotensive human obesity. Hypertension 52: 687-695, 2008.
2. Aghamohammadzadeh R, Heagerty AM. Obesity-related hypertension: epidemiology, pathophysiology, treatments, and the contribution of perivascular adipose tissue. Ann Med 44, Suppl 1: S74-S84, 2012.
3. Alvarez GE, Ballard TP, Beske SD, Davy KP. Subcutaneous obesity is not associated with sympathetic neural activation. Am J Physiol Heart Circ Physiol 287: H414-H418, 2004.
4. Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural activation in visceral obesity. Circulation 106: 2533-2536, 2002.
5. Antunes-Correa LM, Kanamura BY, Melo RC, Nobre TS, Ueno LM, Franco FG, Roveda F, Braga AM, Rondon MU, Brum PC, Barretto AC, Middlekauff HR, Negrao CE. Exercise training improves neurovascular control and functional capacity in heart failure patients regardless of age. Eur J Prev Cardiol 19: 822-829, 2012.
6. Armitage JA, Burke SL, Prior LJ, Barzel B, Eikelis N, Lim K, Head GA. Rapid onset of renal sympathetic nerve activation in rabbits fed a high-fat diet. Hypertension 60: 163-171, 2012.
7. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 6: 152-158, 2012.
8. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 100: 1254-1262, 2007.
9. Bell DS, Bakris GL, McGill JB. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. Diabetes Obes Metab 11: 234-238, 2009.
10. Bellocchio L, Soria-Gomez E, Quarta C, Metna-Laurent M, Cardinal P, Binder E, Cannich A, Delamarre A, Haring M, Martin- Fontecha M, Vega D, Leste-Lasserre T, Bartsch D, Monory K, Lutz B, Chaouloff F, Pagotto U, Guzman M, Cota D, Marsicano G. Activation of the sympathetic nervous system mediates hypophagic and anxiety-like effects of CB(1) receptor blockade. Proc Natl Acad Sci USA 110: 4786-4791, 2013.
11. Bender R, Jockel KH, Trautner C, Spraul M, Berger M. Effect of age on excess mortality in obesity. JAMA 281: 1498-1504, 1999.
12. Beske SD, Alvarez GE, Ballard TP, Davy KP. Reduced cardiovagal baroreflex gain in visceral obesity: implications for the metabolic syndrome. Am J Physiol Heart Circ Physiol 282: H630-H635, 2002.
13. Bharucha AE, Charkoudian N, Andrews CN, Camilleri M, Sletten D, Zinsmeister AR, Low PA. Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol 295: R874-R880, 2008.
14. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL, Investigators SH. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370: 1393-1401, 2014.
15. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the doubleblind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 58: 765-773, 2011.
16. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Bohm M, Hoppe UC. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 59: 901-909, 2012.
17. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.
18. Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, Haller H, Sweep FC, Diedrich A, Jordan J, Tank J. Catheterbased renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension 60: 1485-1490, 2012.
19. Brooks VL, Shi Z, Holwerda SW, Fadel PJ. Obesity-induced increases in sympathetic nerve activity: sex matters. Auton Neurosci 187: 18-26, 2015.
20. Burns J, Ball SG, Worthy G, Struthers AD, Mary DA, Greenwood JP. Hypertensive left ventricular hypertrophy: a mechanistic approach to optimizing regression assessed by cardiovascular magnetic resonance. J Hypertens 30: 2039-2046, 2012.
21. Burns J, Sivananthan MU, Ball SG, Mackintosh AF, Mary DA, Greenwood JP. Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation 115: 1999-2005, 2007.
22. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117: e510-e526, 2008.
23. Chagnac A, Herman M, Zingerman B, Erman A, Rozen-Zvi B, Hirsh J, Gafter U. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant 23: 3946-3952, 2008.
24. Charkoudian N, Joyner MJ, Barnes SA, Johnson CP, Eisenach JH, Dietz NM, Wallin BG. Relationship between muscle sympathetic nerve activity and systemic hemodynamics during nitric oxide synthase inhibition in humans. Am J Physiol Heart Circ Physiol 291: H1378-H1383, 2006.
25. Chazova I, Schlaich MP. Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY study. Int J Hypertens 2013: 541689, 2013.
26. Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: metaanalysis of individual data from 27 randomised trials. Lancet 380: 581-590, 2012.
27. Correia M, Agapitov A, Sinkey C, Haynes W. Vasodilatation induced by beta2 adrenergic receptor activation is impaired in obese hypertensives before and after weight loss. J Hypertens 28: e437, 2010.
28. Curry TB, Somaraju M, Hines CN, Groenewald CB, Miles JM, Joyner MJ, Charkoudian N. Sympathetic support of energy expenditure and sympathetic nervous system activity after gastric bypass surgery. Obesity (Silver Spring) 21: 480-485, 2013.
29. da Silva AA, do Carmo JM, Wang Z, Hall JE. The brain melanocortin system, sympathetic control, and obesity hypertension. Physiology 29: 196-202, 2014.
30. de Kloet AD, Krause EG, Kim DH, Sakai RR, Seeley RJ, Woods SC. The effect of angiotensin-converting enzyme inhibition using captopril on energy balance and glucose homeostasis. Endocrinology 150: 4114-4123, 2009.
31. Dixon JB, Anderson M, Cameron-Smith D, O’Brien PE. Sustained weight loss in obese subjects has benefits that are independent of attained weight. Obes Res 12: 1895-1902, 2004.
32. Dixon JB, Dixon ME. Combined strategies in the management of obesity. Asia Pac J Clin Nutr 15, Suppl: 63-69, 2006.
33. Dorresteijn JA, Schrover IM, Visseren FL, Scheffer PG, Oey PL, Danser AH, Spiering W. Differential effects of renin-angiotensinaldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: a double-blind, placebo-controlled cross-over trial. J Hypertens 31: 393-403, 2013.
34. Eikelis N, Schlaich M, Aggarwal A, Kaye D, Esler M. Interactions between leptin and the human sympathetic nervous system. Hypertension 41: 1072-1079, 2003.
35. Esler MD, Wallin G, Dorward PK, Eisenhofer G, Westerman R, Meredith I, Lambert G, Cox HS, Jennings G. Effects of desipramine on sympathetic nerve firing and norepinephrine spillover to plasma in humans. Am J Physiol Regul Integr Comp Physiol 260: R817-R823, 1991.
36. Fantuzzi G, Mazzone T. Adipose tissue and atherosclerosis: exploring the connection. Arterioscler Thromb Vasc Biol 27: 996-1003, 2007.
37. Fenton C, Keating GM, Lyseng-Williamson KA. Moxonidine: a review of its use in essential hypertension. Drugs 66: 477-496, 2006.
38. Ferraro S, Perrone-Filardi P, Desiderio A, Betocchi S, D’Alto M, Liguori L, Trimigliozzi P, Turco S, Chiariello M. Left ventricular systolic and diastolic function in severe obesity: a radionuclide study. Cardiology 87: 347-353, 1996.
39. Floras JS, Hara K. Sympathoneural and haemodynamic characteristics of young subjects with mild essential hypertension. J Hypertens 11: 647-655, 1993.
40. Florian JP, Pawelczyk JA. Sympathetic and haemodynamic responses to lipids in healthy human ageing. Exp Physiol 95: 486-497, 2010.
41. Friedman JM. Obesity in the new millennium. Nature 404: 632-634, 2000.
42. Frontoni S, Bracaglia D, Baroni A, Pellegrini F, Perna M, Cicconetti E, Ciampittiello G, Menzinger G, Gambardella S. Early autonomic dysfunction in glucose-tolerant but insulin-resistant offspring of type 2 diabetic patients. Hypertension 41: 1223-1227, 2003.
43. Gariepy G, Nitka D, Schmitz N. The association between obesity and anxiety disorders in the population: a systematic review and metaanalysis. Int J Obes (Lond) 34: 407-419, 2010.
44. Gentile CL, Orr JS, Davy BM, Davy KP. Modest weight gain is associated with sympathetic neural activation in nonobese humans. Am J Physiol Regul Integr Comp Physiol 292: R1834-R1838, 2007.
45. Ghosh A. Effects of daily exercise on blood pressure, plasma glucose, and obesity measures in 55-64-year-old obese Asian Indian men: the Calcutta longitudinal study. Am J Hum Biol 18: 718-721, 2006.
46. Grassi G, Seravalle G, Brambilla G, Buzzi S, Volpe M, Cesana F, Dell’oro R, Mancia G. Regional differences in sympathetic activation in lean and obese normotensive individuals with obstructive sleep apnoea. J Hypertens 32: 383-388, 2014.
47. Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, Giannattasio C, Brunani A, Cavagnini F, Mancia G. Sympathetic activation in obese normotensive subjects. Hypertension 25: 560-563, 1995.
48. Grassi G, Seravalle G, Colombo M, Bolla G, Cattaneo BM, Cavagnini F, Mancia G. Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation 97: 2037-2042, 1998.
49. Grassi G, Seravalle G, Dell’Oro R, Turri C, Bolla GB, Mancia G. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 36: 538-542, 2000.
50. Greenfield JR, Miller JW, Keogh JM, Henning E, Satterwhite JH, Cameron GS, Astruc B, Mayer JP, Brage S, See TC, Lomas DJ, O’Rahilly S, Farooqi IS. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 360: 44-52, 2009.
51. Greenwood JP, Scott EM, Stoker JB, Mary DA. Chronic I(1)-imidazoline agonism: sympathetic mechanisms in hypertension. Hypertension 35: 1264-1269, 2000.
52. Grekin RJ, Dumont CJ, Vollmer AP, Watts SW, Webb RC. Mechanisms in the pressor effects of hepatic portal venous fatty acid infusion. Am J Physiol Regul Integr Comp Physiol 273: R324-R330, 1997.
53. Grekin RJ, Ngarmukos CO, Williams DM, Supiano MA. Renal norepinephrine spillover during infusion of nonesterified fatty acids. Am J Hypertens 18: 422-426, 2005.
54. Gudbjornsdottir S, Friberg P, Elam M, Attvall S, Lonnroth P, Wallin BG. The effect of metformin and insulin on sympathetic nerve activity, norepinephrine spillover and blood pressure in obese, insulin resistant, normoglycemic, hypertensive men. Blood Press 3: 394-403, 1994.
55. Guimaraes PS, Huber DA, Campagnole-Santos MJ, Schreihofer AM. Development of attenuated baroreflexes in obese Zucker rats coincides with impaired activation of nucleus tractus solitarius. Am J Physiol Regul Integr Comp Physiol 306: R681-R692, 2014.
56. Haddock RE, Hill CE. Sympathetic overdrive in obesity involves purinergic hyperactivity in the resistance vasculature. J Physiol 589: 3289-3307, 2011.
57. Hall JE. The kidney, hypertension, and obesity. Hypertension 41: 625-633, 2003.
58. Hall JE, da Silva AA, do Carmo JM, Dubinion J, Hamza S, Munusamy S, Smith G, Stec DE. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem 285: 17271-17276, 2010.
59. Harlan SM, Morgan DA, Dellsperger DJ, Myers MG, Mark AL, Rahmouni K. Cardiovascular and sympathetic effects of disrupting tyrosine 985 of the leptin receptor. Hypertension 57: 627-632, 2011.
60. Harlan SM, Rahmouni K. Neuroanatomical determinants of the sympathetic nerve responses evoked by leptin. Clin Auton Res 23: 1-7, 2013.
61. Hausberg M, Tokmak F, Pavenstadt H, Kramer BK, Rump LC. Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease. J Hypertens 28: 1920-1927, 2010.
62. Head GA, Lim K, Barzel B, Burke SL, Davern PJ. Central nervous system dysfunction in obesity-induced hypertension. Curr Hypertens Rep 16: 466, 2014. 63a.Health and Social Care Information Centre. Statistics on Obesity, Physical Activity, and Diet: England, 2011. Leeds, UK: The Health and Social Care Information Centre, 2011.
63. Hering D, Lambert EA, Marusic P, Ika-Sari C, Walton AS, Krum H, Sobotka PA, Mahfoud F, Bohm M, Lambert GW, Esler MD, Schlaich MP. Renal nerve ablation reduces augmentation index in patients with resistant hypertension. J Hypertens 31: 1893-1900, 2013.
64. Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, Esler MD, Schlaich MP. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension 61: 457-464, 2013.
65. Hering D, Marusic P, Walton AS, Lambert EA, Krum H, Narkiewicz K, Lambert GW, Esler MD, Schlaich MP. Sustained sympathetic and blood pressure reduction 1 year after renal denervation in patients with resistant hypertension. Hypertension 64: 118-124, 2014.
66. Heusser K, Tank J, Diedrich A, Engeli S, Klaua S, Kruger N, Strauss A, Stoffels G, Luft FC, Jordan J. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther 79: 500-508, 2006.
67. Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, Peters T, Sweep FC, Haller H, Pichlmaier AM, Luft FC, Jordan J. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 55: 619-626, 2010.
68. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 43: 642-648, 2004.
69. Huggett RJ, Burns J, Mackintosh AF, Mary DA. Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension 44: 847-852, 2004.
70. Huggett RJ, Hogarth AJ, Mackintosh AF, Mary DA. Sympathetic nerve hyperactivity in non-diabetic offspring of patients with type 2 diabetes mellitus. Diabetologia 49: 2741-2744, 2006.
71. Iantorno M, Campia U, Di Daniele N, Nistico S, Forleo GB, Cardillo C, Tesauro M. Obesity, inflammation and endothelial dysfunction. J Biol Regul Homeost Agents 28: 169-176, 2014.
72. Joyner MJ, Charkoudian N, Wallin BG. Sympathetic nervous system and blood pressure in humans: individualized patterns of regulation and their implications. Hypertension 56: 10-16, 2010.
73. Julius S, Jamerson K. Sympathetics, insulin resistance and coronary risk in hypertension: the ‘chicken-and-egg’ question. J Hypertens 12: 495-502, 1994.
74. Julius S, Valentini M, Palatini P. Overweight and hypertension: a 2-way street? Hypertension 35: 807-813, 2000.
75. Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens 14: 83-90, 2000.
76. Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes 60: 2441-2449, 2011.
77. Key TJ, Schatzkin A, Willett WC, Allen NE, Spencer EA, Travis RC. Diet, nutrition and the prevention of cancer. Public Health Nutr 7: 187-200, 2004.
78. Kobayashi D, Takamura M, Murai H, Usui S, Ikeda T, Inomata J, Takashima S, Kato T, Furusho H, Takeshita Y, Ota T, Takamura T, Kaneko S. Effect of pioglitazone on muscle sympathetic nerve activity in type 2 diabetes mellitus with alpha-glucosidase inhibitor. Auton Neurosci 158: 86-91, 2010.
79. Krespi PG, Makris TK, Hatzizacharias AN, Triposkiadis P, Tsoukala C, Kyriaki D, Votteas V, Kyriakidis M. Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor- 1 levels in patients with essential hypertension. Cardiovasc Drugs Ther 12: 463-467, 1998.
80. Krum H, Lambert E, Windebank E, Campbell DJ, Esler M. Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension. Am J Physiol Heart Circ Physiol 290: H1706-H1712, 2006.
81. Lambert E, Dawood T, Straznicky N, Sari C, Schlaich M, Esler M, Lambert G. Association between the sympathetic firing pattern and anxiety level in patients with the metabolic syndrome and elevated blood pressure. J Hypertens 28: 543-550, 2010.
82. Lambert E, Sari CI, Dawood T, Nguyen J, McGrane M, Eikelis N, Chopra R, Wong C, Chatzivlastou K, Head G, Straznicky N, Esler M, Schlaich M, Lambert G. Sympathetic nervous system activity is associated with obesity-induced subclinical organ damage in young adults. Hypertension 56: 351-358, 2010.
83. Lambert E, Straznicky N, Eikelis N, Esler M, Dawood T, Masuo K, Schlaich M, Lambert G. Gender differences in sympathetic nervous activity: influence of body mass and blood pressure. J Hypertens 25: 1411-1419, 2007.
84. Lambert E, Straznicky N, Sari CI, Eikelis N, Hering D, Head G, Dixon J, Esler M, Schlaich M, Lambert G. Dyslipidemia is associated with sympathetic nervous activation and impaired endothelial function in young females. Am J Hypertens 26: 250-256, 2013.
85. Lambert EA, Lambert GW. Stress and its role in sympathetic nervous system activation in hypertension and the metabolic syndrome. Curr Hypertens Rep 13: 244-248, 2011.
86. Lambert EA, Rice T, Eikelis N, Straznicky NE, Lambert GW, Head GA, Hensman C, Schlaich MP, Dixon JB. Sympathetic activity and markers of cardiovascular risk in nondiabetic severely obese patients: the effect of the initial 10% weight loss. Am J Hypertens 27: 1308-1315, 2014.
87. Lambert GW, Hering D, Esler MD, Marusic P, Lambert EA, Tanamas SK, Shaw J, Krum H, Dixon JB, Barton DA, Schlaich MP. Response to quality of life after renal denervation. Hypertension 61: e39, 2013.
88. Lambert GW, Straznicky NE, Lambert EA, Dixon JB, Schlaich MP. Sympathetic nervous activation in obesity and the metabolic syndrome— causes, consequences and therapeutic implications. Pharmacol Ther 126: 159-172, 2010.
89. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 61: 1081-1090, 1986.
90. Lee P, Kengne AP, Greenfield JR, Day RO, Chalmers J, Ho KK. Metabolic sequelae of beta-blocker therapy: weighing in on the obesity epidemic? Int J Obes (Lond) 35: 1395-1403, 2011.
91. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 111: 363-368, 2005.
92. Lim K, Burke SL, Head GA. Obesity-related hypertension and the role of insulin and leptin in high-fat-fed rabbits. Hypertension 61: 628-634, 2013.
93. Livingston EH, Zylke JW. Progress in obesity research: reasons for optimism. JAMA 308: 1162-1164, 2012.
94. Loesch A, Maynard KI, Burnstock G. Calcitonin gene-related peptideand neuropeptide Y-like immunoreactivity in endothelial cells after long-term stimulation of perivascular nerves. Neuroscience 48: 723-726, 1992.
95. Lohmeier TE, Iliescu R, Dwyer TM, Irwin ED, Cates AW, Rossing MA. Sustained suppression of sympathetic activity and arterial pressure during chronic activation of the carotid baroreflex. Am J Physiol Heart Circ Physiol 299: H402-H409, 2010.
96. Lohmeier TE, Iliescu R, Liu B, Henegar JR, Maric-Bilkan C, Irwin ED. Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension 59: 331-338, 2012.
97. Machleidt F, Simon P, Krapalis AF, Hallschmid M, Lehnert H, Sayk F. Experimental hyperleptinemia acutely increases vasoconstrictory sympathetic nerve activity in healthy humans. J Clin Endocrinol Metab 98: E491-H496, 2013.
98. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Bohm M. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 123: 1940-1946, 2011.
99. Mancia G, Parati G. The role of blood pressure variability in end-organ damage. J Hypertens Suppl 21: S17-S23, 2003.
100. Masajtis-Zagajewska A, Majer J, Nowicki M. Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial. Hypertens Res 33: 348-353, 2010.
101. Masuo K, Katsuya T, Kawaguchi H, Fu Y, Rakugi H, Ogihara T, Tuck ML. Beta2-adrenoceptor polymorphisms relate to obesity through blunted leptin-mediated sympathetic activation. Am J Hypertens 19: 1084-1091, 2006.
102. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 42: 474-480, 2003.
103. Masuo K, Rakugi H, Ogihara T, Esler MD, Lambert GW. Effects of weight loss on renal function in overweight Japanese men. Hypertens Res 34: 915-921, 2011.
104. Masuo K, Rakugi H, Ogihara T, Lambert GW. Different mechanisms in weight loss-induced blood pressure reduction between a calorierestricted diet and exercise. Hypertens Res 35: 41-47, 2012.
105. Mathai ML, Naik S, Sinclair AJ, Weisinger HS, Weisinger RS. Selective reduction in body fat mass and plasma leptin induced by angiotensin-converting enzyme inhibition in rats. Int J Obes (Lond) 32: 1576-1584, 2008.
106. Matsukawa T, Gotoh E, Hasegawa O, Miyajima E, Shionoiri H, Tochikubo O, Ishii M. Reduced arterial baroreflex control of muscle sympathetic nerve activity in young borderline hypertensives. Funct Neurol 6: 113-120, 1991.
107. Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb 18: 629-639, 2011.
108. McCully BH, Hasan W, Streiff CT, Houle JC, Woodward WR, Giraud GD, Brooks VL, Habecker BA. Sympathetic cardiac hyperinnervation and atrial autonomic imbalance in diet-induced obesity promote cardiac arrhythmias. Am J Physiol Heart Circ Physiol 305: H1530-H1537, 2013.
109. Millar PJ, Floras JS. Statins and the autonomic nervous system. Clin Sci (Lond) 126: 401-415, 2014.
110. Mingorance C, Alvarez de Sotomayor M, Jimenez-Palacios FJ, Callejon Mochon M, Casto C, Marhuenda E, Herrera MD. Effects of chronic treatment with the CB1 antagonist, rimonabant on the blood pressure, and vascular reactivity of obese Zucker rats. Obesity (Silver Spring) 17: 1340-1347, 2009.
111. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G, Rubino F. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366: 1577-1585, 2012.
112. Miyajima E, Yamada Y, Matsukawa T, Tochikubo O, Ishii M, Kaneko Y. Neurogenic abnormalities in young borderline hypertensives. Clin Exp Hyperetens A 10, Suppl 1: 209-223, 1988.
113. Monroe MB, Van Pelt RE, Schiller BC, Seals DR, Jones PP. Relation of leptin and insulin to adiposity-associated elevations in sympathetic activity with age in humans. Int J Obes Relat Metab Disord 24: 1183-1187, 2000.
114. Montero D, Walther G, Perez-Martin A, Roche E, Vinet A. Endothelial dysfunction, inflammation, and oxidative stress in obese children and adolescents: markers and effect of lifestyle intervention. Obes Rev 13: 441-455, 2012.
115. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature 443: 289-295, 2006.
116. Muntzel MS, Al-Naimi OA, Barclay A, Ajasin D. Cafeteria diet increases fat mass and chronically elevates lumbar sympathetic nerve activity in rats. Hypertension 60: 1498-1502, 2012.
117. O’Brien PE, Dixon JB, Laurie C, Skinner S, Proietto J, McNeil J, Strauss B, Marks S, Schachter L, Chapman L, Anderson M. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med 144: 625-633, 2006.
118. Owlya R, Vollenweider L, Trueb L, Sartori C, Lepori M, Nicod P, Scherrer U. Cardiovascular and sympathetic effects of nitric oxide inhibition at rest and during static exercise in humans. Circulation 96: 3897-3903, 1997.
119. Padwal R, Mamdani M, Alter DA, Hux JE, Rothwell DM, Tu K, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes in an elderly cohort. Diabetes Care 27: 2458-2463, 2004.
120. Palatini P, Mormino P, Dorigatti F, Santonastaso M, Mos L, De Toni R, Winnicki M, Dal Follo M, Biasion T, Garavelli G, Pessina AC, Group HS. Glomerular hyperfiltration predicts the development of microalbuminuria in stage 1 hypertension: the HARVEST. Kidney Int 70: 578-584, 2006.
121. Palatini P, Vriz O, Nesbitt S, Amerena J, Majahalme S, Valentini M, Julius S. Parental hyperdynamic circulation predicts insulin resistance in offspring: The Tecumseh Offspring Study. Hypertension 33: 769-774, 1999.
122. Penumarti A, Abdel-Rahman AA. The novel endocannabinoid receptor GPR18 is expressed in the rostral ventrolateral medulla and exerts tonic restraining influence on blood pressure. J Pharmacol Exp Ther 349: 29-38, 2014.
123. Pettersson K, Bejne B, Bjork H, Strawn WB, Bondjers G. Experimental sympathetic activation causes endothelial injury in the rabbit thoracic aorta via beta 1-adrenoceptor activation. Circ Res 67: 1027-1034, 1990.
124. Pietrasik G, Goldenberg I, McNitt S, Moss AJ, Zareba W. Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients. J Cardiovasc Electrophysiol 18: 181-184, 2007.
125. Praga M, Hernandez E, Herrero JC, Morales E, Revilla Y, Diaz- Gonzalez R, Rodicio JL. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 58: 2111-2118, 2000.
126. Prior LJ, Eikelis N, Armitage JA, Davern PJ, Burke SL, Montani JP, Barzel B, Head GA. Exposure to a high-fat diet alters leptin sensitivity and elevates renal sympathetic nerve activity and arterial pressure in rabbits. Hypertension 55: 862-868, 2010.
127. Rahmouni K. Leptin-induced sympathetic nerve activation: signaling mechanisms and cardiovascular consequences in obesity. Curr Hypertens Rev 6: 104-209, 2010.
128. Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension 45: 9-14, 2005.
129. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988.
130. Robinson LE, Holt TA, Rees K, Randeva HS, O’Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 3: e001986, 2013.
131. Roriz-Filho JS, Sá-Roriz TM, Rosset I, Camozzato AL, Santos AC, Chaves ML, Moriguti JC, Roriz-Cruz M. (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta 1792: 432-443, 2009.
132. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335: 1194-1199, 2007.
133. Sartor DM, Verberne AJ. Abdominal vagal signalling: a novel role for cholecystokinin in circulatory control? Brain Res Rev 59: 140-154, 2008.
134. Sartor DM, Verberne AJ. Gastric leptin: a novel role in cardiovascular regulation. Am J Physiol Heart Circ Physiol 298: H406-H414, 2010.
135. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101: 1899-1906, 2000.
136. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, Thomas S, Abood B, Nissen SE, Bhatt DL. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 366: 1567-1576, 2012.
137. Scheen AJ. Cardiovascular risk-benefit profile of sibutramine. Am J Cardiovasc Drugs 10: 321-334, 2010.
138. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 108: 560-565, 2003.
139. Schobel HP, Heusser K, Schmieder RE, Veelken R, Fischer T, Luft FC. Evidence against elevated sympathetic vasoconstrictor activity in borderline hypertension. J Am Soc Nephrol 9: 1581-1587, 1998.
140. Schreihofer AM, Mandel DA, Mobley SC, Stepp DW. Impairment of sympathetic baroreceptor reflexes in obese Zucker rats. Am J Physiol Heart Circ Physiol 293: H2543-H2549, 2007.
141. Seravalle G, Colombo M, Perego P, Giardini V, Volpe M, Dell’Oro R, Mancia G, Grassi G. Long-term sympathoinhibitory effects of surgically induced weight loss in severe obese patients. Hypertension 64: 431-437, 2014.
142. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 31: 409-414, 1998.
143. Simonds SE, Cowley MA, Enriori PJ. Leptin increasing sympathetic nerve outflow in obesity: A cure for obesity or a potential contributor to metabolic syndrome? Adipocyte 1: 177-181, 2012.
144. Sjostrom CD, Peltonen M, Wedel H, Sjostrom L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 36: 20-25, 2000.
145. Skarphedinsson JO, Elam M, Jungersten L, Wallin BG. Sympathetic nerve traffic correlates with the release of nitric oxide in humans: implications for blood pressure control. J Physiol 501: 671-675, 1997.
146. Skilton MR, Moulin P, Terra JL, Bonnet F. Associations between anxiety, depression, and the metabolic syndrome. Biol Psychiatry 62: 1251-1257, 2007.
147. Smith MM, Minson CT. Obesity and adipokines: effects on sympathetic overactivity. J Physiol 590: 1787-1801, 2012.
148. Snitker S, Tataranni PA, Ravussin E. Respiratory quotient is inversely associated with muscle sympathetic nerve activity. J Clin Endocrinol Metab 83: 3977-3979, 1998.
149. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 96: 1897-1904, 1995.
150. Spraul M, Ravussin E, Fontvieille AM, Rising R, Larson DE, Anderson EA. Reduced sympathetic nervous activity. a potential mechanism predisposing to body weight gain. J Clin Invest 92: 1730-1735, 1993.
151. Strand AH, Gudmundsdottir H, Os I, Smith G, Westheim AS, Bjornerheim R, Kjeldsen SE. Arterial plasma noradrenaline predicts left ventricular mass independently of blood pressure and body build in men who develop hypertension over 20 years. J Hypertens 24: 905-913, 2006.
152. Straznicky NE, Eikelis N, Lambert EA, Esler MD. Mediators of sympathetic activation in metabolic syndrome obesity. Curr Hypertens Rep 10: 440-447, 2008.
153. Straznicky NE, Grima MT, Eikelis N, Nestel PJ, Dawood T, Schlaich MP, Chopra R, Masuo K, Esler MD, Sari CI, Lambert GW, Lambert EA. The effects of weight loss versus weight loss maintenance on sympathetic nervous system activity and metabolic syndrome components. J Clin Endocrinol Metab 96: E503-E508, 2011.
154. Straznicky NE, Grima MT, Lambert EA, Eikelis N, Dawood T, Lambert GW, Nestel PJ, Masuo K, Sari CI, Chopra R, Mariani JA, Schlaich MP. Exercise augments weight loss induced improvement in renal function in obese metabolic syndrome individuals. J Hypertens 29: 553-564, 2011.
155. Straznicky NE, Grima MT, Lambert EA, Sari CI, Eikelis N, Nestel PJ, Phillips SE, Hering D, Karapanagiotidis S, Dixon JB, Schlaich MP, Lambert GW. Arterial norepinephrine concentration is inversely and independently associated with insulin clearance in obese individuals with metabolic syndrome. J Clin Endocrinol Metab 100: 1544-1550, 2015.
156. Straznicky NE, Grima MT, Sari CI, Eikelis N, Lambert EA, Nestel PJ, Esler MD, Dixon JB, Chopra R, Tilbrook AJ, Schlaich MP, Lambert GW. Neuroadrenergic dysfunction along the diabetes continuum: a comparative study in obese metabolic syndrome subjects. Diabetes 61: 2506-2516, 2012.
157. Straznicky NE, Grima MT, Sari CI, Eikelis N, Lambert GW, Nestel PJ, Karapanagiotidis S, Wong C, Richards K, Marusic P, Dixon JB, Schlaich MP, Lambert EA. A randomized controlled trial of the effects of pioglitazone treatment on sympathetic nervous system activity and cardiovascular function in obese subjects with metabolic syndrome. J Clin Endocrinol Metab 99: E1701-E1707, 2014.
158. Straznicky NE, Lambert EA, Lambert GW, Masuo K, Esler MD, Nestel PJ. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab 90: 5998-6005, 2005.
159. Straznicky NE, Lambert EA, Nestel PJ, McGrane MT, Dawood T, Schlaich MP, Masuo K, Eikelis N, de Courten B, Mariani JA, Esler MD, Socratous F, Chopra R, Sari CI, Paul E, Lambert GW. Sympathetic neural adaptation to hypocaloric diet with or without exercise training in obese metabolic syndrome subjects. Diabetes 59: 71-79, 2010.
160. Straznicky NE, Lambert GW, Masuo K, Dawood T, Eikelis N, Nestel PJ, McGrane MT, Mariani JA, Socratous F, Chopra R, Esler MD, Schlaich MP, Lambert EA. Blunted sympathetic neural response to oral glucose in obese subjects with the insulin-resistant metabolic syndrome. Am J Clin Nutr 89: 27-36, 2009.
161. Sverrisdottir YB, Jansson LM, Hagg U, Gan LM. Muscle sympathetic nerve activity is related to a surrogate marker of endothelial function in healthy individuals. PLoS One 5: e9257, 2010.
162. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 57: 911-917, 2011.
163. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376: 1903-1909, 2010.
164. Tentolouris N, Liatis S, Katsilambros N. Sympathetic system activity in obesity and metabolic syndrome. Ann NY Acad Sci 1083: 129-152, 2006.
165. Tonacio AC, Trombetta IC, Rondon MU, Batalha LT, Kuniyoshi FH, Laterza MC, Suzuki PH, Gowdak MM, Barretto AC, Halpern A, Villares SM, Negrão CE. Effects of diet and exercise training on neurovascular control during mental stress in obese women. Braz J Med Biol Res 39: 53-62, 2006.
166. Topal E, Cikim AS, Cikim K, Temel I, Ozdemir R. The effect of moxonidine on endothelial dysfunction in metabolic syndrome. Am J Cardiovasc Drugs 6: 343-348, 2006.
167. Trombetta IC, Batalha LT, Rondon MU, Laterza MC, Kuniyoshi FH, Gowdak MM, Barretto AC, Halpern A, Villares SM, Negrao CE. Weight loss improves neurovascular and muscle metaboreflex control in obesity. Am J Physiol Heart Circ Physiol 285: H974-H982, 2003.
168. van Baak MA. Meal-induced activation of the sympathetic nervous system and its cardiovascular and thermogenic effects in man. Physiol Behav 94: 178-186, 2008.
169. Van Vliet BN, Hall JE, Mizelle HL, Montani JP, Smith MJ. Reduced parasympathetic control of heart rate in obese dogs. Am J Physiol Heart Circ Physiol 269: H629-H637, 1995.
170. Vaz M, Jennings G, Turner A, Cox H, Lambert G, Esler M. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 96: 3423-3429, 1997.
171. Vaz M, Turner A, Kingwell B, Chin J, Koff E, Cox H, Jennings G, Esler M. Postprandial sympatho-adrenal activity: its relation to metabolic and cardiovascular events and to changes in meal frequency. Clin Sci (Lond) 89: 349-357, 1995.
172. Verloop WL, Spiering W, Vink EE, Beeftink MM, Blankestijn PJ, Doevendans PA, Voskuil M. Denervation of the renal arteries in metabolic syndrome: the DREAMS-study. Hypertension 65: 751-757, 2015.
173. Vest AR, Heneghan HM, Schauer PR, Young JB. Surgical management of obesity and the relationship to cardiovascular disease. Circulation 127: 945-959, 2013.
174. Vonend O, Marsalek P, Russ H, Wulkow R, Oberhauser V, Rump LC. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 21: 1709-1717, 2003.
175. Wallbach M, Lehnig LY, Schroer C, Helms HJ, Luders S, Patschan D, Patschan S, Muller GA, Wachter R, Koziolek MJ. Effects of baroreflex activation therapy on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Hypertens 33: 181-186, 2014.
176. Wang J, Wang H, Luo W, Guo C, Wang J, Chen YE, Chang L, Eitzman DT. Leptin-induced endothelial dysfunction is mediated by sympathetic nervous system activity. J Am Heart Assoc 2: e000299, 2013.
177. Witkowski A, Prejbisz A, Florczak E, Kadziela J, Sliwinski P, Bielen P, Michalowska I, Kabat M, Warchol E, Januszewicz M, Narkiewicz K, Somers VK, Sobotka PA, Januszewicz A. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 58: 559-565, 2011.
178. Wong CY, O’Moore-Sullivan T, Leano R, Hukins C, Jenkins C, Marwick TH. Association of subclinical right ventricular dysfunction with obesity. J Am Coll Cardiol 47: 611-616, 2006.
179. Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Papademetriou V. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J 34: 2132-2140, 2013.
180. Yokoe H, Yuasa F, Yuyama R, Murakawa K, Miyasaka Y, Yoshida S, Tsujimoto S, Sugiura T, Iwasaka T. Effect of pioglitazone on arterial baroreflex sensitivity and sympathetic nerve activity in patients with acute myocardial infarction and type 2 diabetes mellitus. J Cardiovasc Pharmacol 59: 563-569, 2012.
181. Young CN, Morgan DA, Butler SD, Mark AL, Davisson RL. The brain subfornical organ mediates leptin-induced increases in renal sympathetic activity but not its metabolic effects. Hypertension 61: 737-744, 2013.
182. Young JB, Macdonald IA. Sympathoadrenal activity in human obesity: heterogeneity of findings since 1980. Int J Obes Relat Metab Disord 16: 959-967, 1992.